News

(RTTNews) - Annexon, Inc. (ANNX) on Tuesday said that the Phase 3 trial of ANX005 in patients with Guillain-Barre syndrome (GBS) met its primary goal. GBS is a rare auto immune disorder affecting the nerves.

In the Phase 3 study, a single infusion of ANX005 30 mg/kg achieved a highly statistically significant 2.4-fold improvement on the GBS-disability scale (GBS-DS) at week 8. ANX005 30 mg/kg treatment also showed improvements on key secondary endpoints, including early gains in muscle strength, fewer days on artificial ventilation, and reduction in nerve damage compared with placebo.

Real-World Evidence (RWE) comparability data and BLA submission are expected in first half of 2025.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.